Sangamo sells Fabry gene therapy ST-920 to PTC for $111M cash; Nasdaq delisting Sept 27

SANGAMO THERAPEUTICS, INC

Completed Sept 17, 2026 sale of ST-920 (isaralgagene civaparvovec) to PTC Therapeutics for $111M cash at close.
Up to $100M in additional milestone-based contingent consideration; PTC assumes specified liabilities.
Court approved sale Sept 2, 2026 (Docket No. 426) following Aug 10 auction where PTC was successful bidder.
Nasdaq delisting effective Sept 27, 2026 after Form 25 filed Sept 17; stock trades OTC under SGMOQ.
Company operates as debtor-in-possession in Chapter 11 Case No. 26-10989 (Delaware Bankruptcy Court).

Featured in Daily 8-K Digest

Selected #2 for 2026-09-21. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.